A-share subscription | Tenomaybo (688806.SH) starts subscription The world's first approved Steduta monoclonal antibody injection solution has been listed.

According to the Securities Times app, on July 10th, Temo Micro (688806.SH) started its subscription with an issue price of 14.46 yuan per share and a subscription limit of 11,500 shares. It is listed on the Shanghai Stock Exchange, and Huatai Securities is its sponsoring institution.